Treats relapsing forms of multiple sclerosis (MS). ANDA 90218, held by Sandoz. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 90218 (Glatopa), held by Sandoz, was first approved by FDA on Apr 16, 2015, with 12 approved supplements and 0 published complete response letters.
Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatopa20MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
| Feb 12, 2026 | Supplement 32Labeling · Standard review | Approved | None posted |
| Mar 7, 2025 | Supplement 31Labeling · Standard review | Approved | None posted |
| Mar 19, 2024 | Supplement 28Labeling · Standard review | Approved | None posted |
| May 8, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 25Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 24Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 16, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters